• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Lantheus Holdings Inc.

    5/5/25 4:26:23 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LNTH alert in real time by email
    8-K
    false 0001521036 --12-31 0001521036 2025-05-01 2025-05-01
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 1, 2025

     

     

    LANTHEUS HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-36569   35-2318913

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

    201 Burlington Road, South Building

    Bedford, Massachusetts 01730

    (Address of principal executive offices) (Zip code)

    Registrant’s telephone number, including area code: (978) 671-8001

    Not Applicable

    (Former name or former address, if changed since last report.)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common stock, par value $0.01 per share   LNTH   The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.03

    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    On May 1, 2025, the Board of Directors of Lantheus Holdings, Inc. (the “Company”) amended and restated the Company’s Bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective immediately. Among other things, the amendments effected by the Amended and Restated Bylaws (i) add procedural and disclosure requirements for stockholders calling special meetings of stockholders, (ii) update procedures and rules relating to stockholder meetings, (iii) revise procedural mechanics and disclosure requirements applicable to stockholder nominations of directors, submissions of proposals regarding other business at stockholder meetings, proxy access and general director eligibility, (iv) provide that the authorized number of directors is automatically reduced upon any vacancy on the Board of Directors of the Company to eliminate such vacancy, (v) make certain changes to conform to recent amendments to the Delaware General Corporation Law and (vi) make certain other ministerial changes.

    This description of the amendments to the Amended and Restated Bylaws is qualified in its entirety by reference to the text of the Amended and Restated Bylaws, which is attached hereto as Exhibit 3.2 and incorporated herein by reference.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders

    The Annual Meeting of Stockholders (the “Annual Meeting”) of the Company was held on May 1, 2025. Set forth below is a brief description of each matter submitted to a vote of the Company’s stockholders at the Annual Meeting and the final voting results for each matter. A more complete description of each matter is set forth in the Company’s definitive proxy statement for the Annual Meeting, which was filed with the Securities and Exchange Commission on March 21, 2025.

    Proposal 1 – Election of Directors

    Each of the following nominees for Class I director was elected by the Company’s stockholders to serve a three-year term expiring at 2028 Annual Meeting of Stockholders based on the following vote:

     

    Nominee

       Votes For      Votes Against      Abstentions      Broker Non-Votes  

    Mary Anne Heino

         54,279,288.86        6,466,902.18        35,424        3,910,309  

    Dr. Gérard Ber

         57,213,631.86        3,531,659.18        36,324        3,910,309  

    Julie Eastland

         56,063,803.86        4,678,328.18        39,483        3,910,309  

    Samuel Leno

         41,497,552.86        19,245,001.18        39,061        3,910,309  

    Proposal 2 – Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers

    The approval, on an advisory basis, of the compensation paid to the Company’s named executive officers was approved by the Company’s stockholders based on the following vote:

     

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non-Votes

    57,776,739.23   2,835,657.28   169,218.53   3,910,309

    Proposal 3 – Ratification of Appointment of Deloitte & Touche LLP

    The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified by the Company’s stockholders based on the following vote:

     

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non-Votes

    64,158,082.04   496,039   37,803   0


    Proposal 4 – Approve the stockholder proposal regarding the declassification of the Company’s Board of Directors.

    The stockholder proposal regarding the declassification of the Company’s Board of Directors was approved on an advisory basis by the Company’s stockholders based on the following vote:

     

    Votes For

     

    Votes Against

     

    Abstentions

     

    Broker Non-Votes

    59,250,670.33   703,194.16   713,510.55   4,024,549

     

    Item 9.01

    Financial Statements and Exhibits

    (d) Exhibits

     

    Exhibit

    Number

      

    Exhibit Description

    3.2*    Amended and Restated Bylaws of Lantheus Holdings, Inc.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    *

    Filed herewith.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    LANTHEUS HOLDINGS, INC.
    By:  

    /s/ Daniel Niedzwiecki

    Name:   Daniel Niedzwiecki
    Title:   Chief Administrative Officer and General Counsel

    Date: May 5, 2025

    Get the next $LNTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LNTH

    DatePrice TargetRatingAnalyst
    12/18/2024$143.00Buy
    Goldman
    9/3/2024$175.00Buy
    Redburn Atlantic
    7/10/2024$100.00 → $130.00Mkt Outperform
    JMP Securities
    12/18/2023Outperform → Mkt Perform
    William Blair
    12/4/2023$100.00Outperform
    TD Cowen
    9/29/2023Outperform
    William Blair
    3/8/2023$120.00Mkt Outperform
    JMP Securities
    11/30/2022Outperform
    SVB Leerink
    More analyst ratings